Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

ConditionNMIBC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChanghai Hospital

About this trial

Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.

Eligibility criteria

Qualifiers

High-grade T1

Any recurrent high-grade Ta

High-grade Ta & Tumor diameter greater than 3 cm or multifocal

Any CIS

Disqualifiers

Bladder cancer other than UC

MIBC or benign diseases

Incomplete tumor resection

Active infection

Trial design

Treatments tested in this trial

  • Immediate postoperative chemotherapy

Treatment groups

72 Participants
are divided into 1 treatment group

Sponsors and collaborators